SK1-I

N/A

Report date: 2022/04/29 18:04:00

Base Information

Drug NameSK1-I
Drug Alias NameSK1-IBML-258
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine kinase 2 inhibitors
TargetsSphingosine kinase 2
Therapy Area/IndicationsSolid tumoursLupus Erythematosus, SystemicHepatitis, Autoimmune +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEnzoVirginia Commonwealth University
China Registration ClassN/A

Develop Information

Active CompaniesEnzoVirginia Commonwealth University
Inactive CompaniesN/A
Active IndicationsSolid tumoursLupus Erythematosus, SystemicHepatitis, Autoimmune +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A